Trial Profile
swiTching From etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluatinG the efficacy, tOlerance and safety
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms TANGO
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 25 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2009 New trial record.